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Adoptivetransferofeﬀectorantigen-speciﬁcimmunecellsisbecomingapromisingtreatmentoptioninallogeneictransplantation,
infectious diseases, cancer, and autoimmune disorders. Within this context, the important role of CD8+ cytotoxic T cells (CTLs)
is objective of intensive studies directed to their in vivo and ex vivo induction, detection, selection, expansion, and therapeutic
eﬀectiveness. Additional questions that are being addressed by the scientiﬁc community are related to the establishment and
maintenance of their longevity and memory state as well as to deﬁning critical conditions underlying their transitions between
discrete, but functionally diﬀerent subtypes. In this article we review and comment latest approaches and techniques used for
preparing large amounts of antigen-speciﬁc CTLs, suitable for clinical use.
1.Introduction
Adoptive transfer of antigen-speciﬁc cytotoxic CD8+ T
cells (CTLs) represents a promising approach especially
in treating certain highly immunogenic tumors and viral
infections. The production of clinical-grade eﬀector T lym-
phocyteshasevolvedfromarathersimpleandclinicallyquite
disappointing use of ex vivo lymphokine-activated killer cell
(LAK) preparation, followed by the equally poorly eﬀective
andtoxicsystemicuseofhighconcentrationsofrecombinant
interleukin-2 (IL-2) to far more promising applications of
in vitro expanded tumor-inﬁltrating lymphocytes (TILs)
leading to and demanding technically complex cell bioengi-
neering processes, requiring speciﬁc immune cell subtype
isolation, clonal selection, genetic modiﬁcation, as well as
other extensive in vitro manipulations in order to obtain
suﬃcient numbers of deﬁned therapeutically eﬀective cellu-
lar products. The understanding and considering of speciﬁc
and complex mechanisms, characteristic of cell biology and
physiology, are keys to successful ex vivo preparation and in
vivo application of selected antigen-speciﬁc immune cells.
Therefore we will ﬁrst review the key mechanisms of CD8+ T
cell antigen recognition, their subsequent clonal activation,
and eﬀector function.
2.CD8+ T Lymphocyte Antigen Recognition,
ClonalActivation,EffectorFunction,and
Memory Cell Pool Transition
Blood of normal individuals contains 5–12,5 × 109 T cells,
among which are 2,5–8,4 × 109 CD4+ and 1,5–4,5× 109
CD8+ T lymphocytes, resulting in a stable physiological
CD4+/CD8+ cell ratio of 1,5. The size of the periph-
eral pool of na¨ ıve T cells is kept remarkably constant
by poorly understood homeostatic mechanisms based on
the perpetuum interplay between lymphogenesis, selective
transition of newly emerged cells into a long-lived pool, the
extentoflymphocytesurvivalintheperipheryaswellastheir
depletion following antigen-induced immune responses.2 Journal of Biomedicine and Biotechnology
In order to diﬀerentiate into cytotoxic eﬀectors or memory
CD8+ T lymphocytes, being able to traﬃct on o n l y m p h o i d
tissues, the na¨ ıve CD8+ antigen-speciﬁc precursor T cells
havetobeactivatedwithinthelymphoidorgans,especiallyin
the immunogen-draining lymph nodes. Here the na¨ ıve cells
ﬁrst upregulate the expression of the chemokine receptor
CCR5 which enables them to come into close contact with
the sites of antigen presenting dendritic cell (DC)-antigen-
speciﬁc CD4+ helper T cell (Th) interactions where the cog-
nate attraction chemokines CCL3 and CCL4 are produced
[1]. Finally, through the orchestrated cell-cell contacts, the
optimalantigen-speciﬁcCD8+ cytotoxiceﬀectorTcellclones
(CTLs) are generated. The CTL responses to majority of
antigens are Th cell-dependent. Namely, Th cells are able,
through direct cell-cell interaction, to instruct and activate
antigen-presenting cells (APCs) in such a way that they
can then directly prime CTLs. This eﬀect is referred to as
the “licence to kill”. Also, by paracrine secretion, Th cells
provide IL-2, needed for both their own clonal expansion
as well as for starting and supporting the na¨ ıve CD8+ Tc e l l
diﬀerentiation. Probably because of the fact that CTLs are
so very much eﬀective in delivering death signals to their
targets, the na¨ ıve CD8+ T cells require more costimulation
in order to become fully armed cytotoxic eﬀectors, when
compared to CD4+ Tl y m p h o c y t e s .
Beside a classical activation strictly by intracellular
antigen presentation within the context of extremely poly-
morphic major histocompatibility complex (MHC) class I
molecules, the so-called class I human leukocyte antigens
(HLA), expressed on the surface of APCs, na¨ ıve CD8+
T cells can also be stimulated via the so-called cross-
presentation, resulting in cross-priming of precursor CTLs.
This kind of CTL generation has ﬁrst been evidenced and
reported already in 1976, by Bevan [2]. It plays a role
in the immune defence against many viruses (HPV, CMV,
EBV, Inﬂuenza, Papilloma, ...) and several bacteria (Listeria,
Salmonella, E. coli,...) which do not infect APCs as well
as against most types of tumors that can avoid immune
surveillancethrough diﬀerent mechanisms, forexample, also
by suppressing normal antigen processing pathways [3, 4].
Namely, not only certain APCs, primarily dendritic cells
(DCs) and macrophages, but also, although less eﬃciently, B
lymphocytes, neutrophils, liver sinusoidal endothelial cells,
and bone marrow mesenchymal stromal cells, are able to
take up and then process and present extracellular antigens
through their class I MHC antigen-loading pathway [5–7].
Theexactmechanismbywhichexogenousantigensreachthe
cytosol, where they enter the MHC class I antigen-processing
and -loading machinery, is still unclear. However, profes-
sional APCs (DCs, macrophages) can engulf dead, infected
and tumor cells or their debris by phagocytosis, receptor-
mediated endocytosis, macropinocytosis, and pinocytosis
and possibly also by seeping through gap junctions [8–10].
Endosomesareformed,containingtheextracellularmaterial,
which fuse with lysosomes and the antigenic degradation
starts. Once released in cytosol, the exogenous proteins are
ubiquitylated to enter proteasome where they are cleaved in
peptides. These are then translocated into the endoplasmatic
reticulum (ER) by the heterodimeric transporter associated
with antigen processing (TAP) and further degraded in
smaller peptides, typically of 8 to 10 amino acids. The
antigenloadingsetofnascentMHCclassI–β2-microglobulin
molecular complex associated with tapasin, calreticulin, and
ERp57 ﬁnally directs the peptide into the antigen-binding
groove of the class I molecule. The antigenic peptide-loaded
MHC class I molecules are then transported to the cell
surface via the Golgi apparatus [11, 12]. Such primed cross-
presenting APCs can thereby directly stimulate na¨ ıve CD8+
T cells [13].
Basically, each eﬀective T cell response to a given antigen
depends on three complementary signals. The ﬁrst one,
deﬁning its speciﬁcity, is provided by the interaction of the
clonal T cell receptor (TCR), which in more than 90% is
animmunoglobulin-likedisulﬁde-linkedαβ transmembrane
heterodimer, expressed on the responding antigen-speciﬁc
CD8+ or CD4+ T cell and the antigenic peptide presented
within the antigen-binding groove of a particular HLA
class I (generally the intracellular antigens) or class II
molecule (generally the extracellular antigens) present on
the surface of a professional APC [14]. The genes coding
for TCR α and β chains arise from rearranged germline-
encoded gene segments. Genes encoding for the α chain
are products of recombination of variable (V), junctional
(J), and constant (C) gene segments, while those encod-
ing for the β chain result from recombination of V, J,
diversity (D), and C gene segments. The speciﬁc ligand-
binding site of each TCR is composed out of two Vα and
two Vβ encoded complementarity-determining regions or
CDR loops (CDR1α, CDR1β, CDR2α, CDR2β) and two
junctional CD3 loops (CD3α,C D 3 β). While the Vα and
Vβ encoded CDR1 and CDR2 loops primarily interact
with α helices surrounding the peptide-binding groove of
a MHC molecule, the hyper variable CDR3 loop interacts
with amino acid residues of the antigenic peptide, bound
into the highly polymorphic peptides binding groove of
the MHC molecule [15, 16]. The clonotypic TCR-MHC-
antigenic peptide interaction is stabilised and enhanced
by the interaction of T cell-speciﬁc CD4+ monomers or
homodimers with invariant parts of HLA class II molecules
and in case of highly glycosylated CD8+ αβ heterodimers or
αα homodimers with the base of the constant α2 domains
of HLA class I molecules [17]. It has been shown that CD4
or CD8 binding to corresponding MHC molecules increases
the sensitivity of T cells for antigen presentation by ∼100-
fold. Both, CD4, and CD8 bind Lck tyrosine kinase to their
cytoplasmic tails and while interacting bring it close to
the TCR [18]. When the reaction threshold between TCR,
CD4/CD8, and antigenic peptide-MHC molecule complexes
is reached, the activation signal is transmitted to the T cell
nucleus. For this to be eﬀective, a complete TCR complex is
required. The CD3 molecular cluster, adjacent to the TCR
and composed out of two ε,o n eδ and one γ transmembrane
subunits, both stabilises TCR cell surface expression and is
involved in activation signalling, as each of them has one
immunoreceptor tyrosine-based activation motif (ITAM)
present on their cytoplasmic structural region [19]. The TCR
complex is also composed of a ζ chain homodimer having
a very short extracellular domain and expressing 3 ITAMsJournal of Biomedicine and Biotechnology 3
per long cytoplasmic tail of each ζ chain. Clustering of TCRs
and their CD4/CD8 coreceptors on binding MHC-antigenic
peptide complexes initiates signalling within the activated
T cell through recruitment of CD4/CD8-associated Lck and
activation of TCR receptor complex associated Fyn tyrosine
kinases which in turn phosphorylate the CD3 ε,δ,a n dγ
as well as ζ chain ITAMs [20]. Activation of these kinases
is mediated by the tyrosine-speciﬁc phosphatase CD45,
the so-called leukocyte common antigen. Subsequently the
tyrosine kinase ZAP70 (zeta-chain-associated protein) binds
to the phosphorylated ITAMs of each ζ chain and is then
phosphorylated by the Lck. This enables the ζζ homodimer
to propagate, through complex signalling cascades, the
activation signal onward to the T cell interior [21, 22].
The second signal is also crucial because if absent,
regardless of the fact that the ﬁrst antigen-speciﬁc signal
is eﬀectively accomplished, such primed T cells become
anergic. Namely, in order to become fully operational and
to undergo clonal expansion, the reacting T cells have to
receive a proper costimulatory signal that is provided by
interactions of T cell-speciﬁc CD28 molecules with their
APC-expressed glycoprotein ligands B7.1 (CD80) and B7.2
(CD86) [23]. As already mentioned, the clonal expansion
of CD8+ T cells requires a stronger costimulatory signal
than that of CD4+ T lymphocytes. When na¨ ıve T cells
become activated, they start to express a number of proteins
able to sustain or modulate the costimulatory signal. One
of them is the CD40 ligand (CD154) which binds to the
CD40 molecule present on APCs. This interaction activates
both T cells as well as APCs, which in turn start to express
B7 costimulatory molecules [24]. The 4-1BB (CD137)
costimulatory molecules, members of the tumor necrosis
factor receptor (TNFR) family, are expressed on a minority
of resting CD8+ T cells and are transiently upregulated by all
activated CD8+ T lymphocytes. They bind their ligands (4-
1BBL, CD137L) present on primed APCs (activated B cells,
DCs, monocytes/macrophages) and thereupon promote
CD8+ T cell proliferation, diﬀerentiation, enhanced eﬀector
cytolitic capacity as well as the inhibition of apoptosis.
Ligation of 4-1BB with 4-1BBL directly augments the
cytotoxic function of activated human CD8+ Tl y m p o c y t e s
and additionally upregulates the expression of the activating
natural killer (NK) cell receptor NKG2D on CTLs [25].
The latter eﬀect is potentially important for the non-MHC-
restricted elimination of infected or malignant cells, being
able to downregulate MHC expression or shed various
NKG2D ligands, for example, MHC-like molecules MIC-A
and MIC-B. It has also been shown recently that while
the CD28 co-stimulation pathway preferentially expands
na¨ ıve CD8+ T cells, the 4-1BB-induced signalling promotes
proliferation of memory CTL populations [25]. Therefore,
it seems that 4-1BB co-stimulation represents an important
tool for ex vivo expansion of higly eﬃcient antigen-speciﬁc
memory CTLs for adoptive immune T cell therapies. One
of the mechanisms that control the extent of proliferative
responses of fully activated T cells depends on the ligation
of CTLA-4 (CD152) and B7 costimulatory molecules.
Namely, fully activated proliferating T cells start to express
CTLA-4, which structurally closely resembles CD28. It
binds approximately 20 times more avidly to B7 molecules
than CD28, thereby delivering negative signals to activated
T cells and limiting the autocrine production of T-cell
growth factor IL-2. Additional inhibitory signals, regulating
the extent of immune response (inhibition of cytokine
expression, cell-cycle arrest, and/or apoptosis) also arise
from the interactions of programmed cell death protein-1
(PD-1) expressed on T lymphocytes and its PD-L1 (B7-H1)
and PD-L2 (B7-DC) binding molecules present on APCs
[26]. Other important immune response regulators are: the
transforming growth factor-β (TGF-β) ,w h i c hi sp r e v a l e n t l y
produced by certain subsets of CD4+ T cells (Th1, Th3, Tr1)
and can inhibit growth as well as promote survival of T
cells, and interleukin-10 (IL-10). IL-10 is produced by many
diﬀerent cell types, for example, B cells, macrophages, Th1,
Th2, Th17, and Tr1 with the latter ones being regulatory
cells that can be generated in the periphery from na¨ ıve
CD4+ Tl y m p h o c y t e s .R e c e n ts t u d i e so fr e g u l a t o r yTc e l l s
have clearly shown their importance in immunosuppressive
modulation of cellular immune responses [27]. They are
characterised by diﬀerent phenotypes: CD4+CD25+FoxP3+
(Treg), CD4+CD25−IL10+IFNγlowIL4− (Tr1), CD4+TGF-
β+ (Th3), CD8+CD25+ that produce TGF-β and express
CTLA-4, CD8+CD28− (Ts) which induce the up-regulation
of immunoglobulin-like transcripts ILT3 and ILT4 on
DCs which in turn become tolerogenic; CD8+CD62L(L-
selectin)+CD122(IL-2Rβ)+,C D 8 +IL10+, and function
through quite distinct mechanisms [28, 29].
The third signal is a polarizing one, determining the
nature of cellular response, being either T helper type 1
(Th1), T helper type 2 (Th2), or T regulatory (Treg). It
is mediated by interactions of both membrane-bound and
prevalently soluble factors, such as interleukin-2 (IL-2),
interleukin-7 (IL-7), interleukin-12 (IL-12), interleukin-15
(IL-15), type I interferons (IFN) or interleukin-10 (IL-10),
produced by APCs as well as reactive T cells, and their
respective cell surface receptors [30, 31].
T h eﬁ r s td i v i s i o no ff u l l ya c t i v a t e dTc e l l so c c u r sa f t e r
48 hours and continues by 3-4 divisions per day, resulting
in a 1000-fold expansion of the responding cell population
within only few days. The initial Th1-dependent, autocrine
IL-2-induced clonal CTL expansion is transient, and already
within 3-4 days, the proliferating cells become activation-
induced nonresponsive (AINR), and due to the lack of IL-2
production in the absence of additional exogenous IL-2 or
appropriate CD4+ T help, their proliferation ceases and their
survival declines. However the TCR-mediated signalling
remains operational, because following the recognition of
MHCclassI-antigenicpeptidecomplexesexpressedontarget
cells, the AINR CTLs produce IFN-γ and carry out their
cytotoxic eﬀector function. Antigen-speciﬁc lysis of target
cells by armed CTLs can start already within 5 minutes and
the killing process can endure over hours [32]. Cytotoxic
T cells kill their targets by inducing their apoptosis or
programmed cell death. Upon antigen-speciﬁc recognition
and close interaction with target cells, CTLs, in a calcium-
dependent way, release specialized lytic granules, which
actually are modiﬁed lysosomes. These intracellular com-
partments contain diﬀerent active cytotoxic proteins, which4 Journal of Biomedicine and Biotechnology
are only eﬀective when released form the granules [33].
One of them is perforin that, after polymerisation, forms
irreversible pores in the membrane of attacked cells. The
CTL lytic granules also contain granzymes, that is, at least
three enzymes pertaining to the family of serine proteases
and granulysin, being able to induce target cell apoptosis
and possessing antimicrobial properties [33]. The surface
mobilizationofLAMP1(CD107a),anintegralcytoliticgran-
ule membrane protein, is a marker of degranulation after
antigenstimulationandcanbemonitoredbyﬂowcytometry,
for example in vaccine trials or in ex vivo expansion of
CTLs for adoptive immunotherapy. As already mentioned,
the granule-mediated killing is calcium dependent, but there
is another apoptotic trigger that is operational even in the
absence of Ca++. Namely, in such conditions, CD8+ eﬀectors
as well as some CD4+ T cells, which constitutively lack
lytic granules, are able to kill their targets. This involves
binding of the Fas ligand (FasL, CD178), a member of the
TNF molecular family, expressed on CTLs and some Th1
as well as Th2 cells, to Fas (CD95), present on antigen-
speciﬁc target cells [34]. Ligation of Fas activates caspases,
cysteine proteases, in target cells, that induce their apoptosis
[35]. Most CTLs also produce and release IFN-γ,I N F - γ,
TNF-α,a n dT N F - β, thereby facilitating host defence against
pathogens. They are able to directly inhibit viral replication,
induce increased expression of MHC class I and other
molecules involved in antigenic peptide presentation, as well
as to activate macrophages [36]. Generally, according to
the cytokine-producing proﬁles, two subtypes of cytotoxic
CD8+ T cells exist. The Tc1 cells have a cytokine secretion
proﬁle similar to Th1 lymphocytes while the Tc2 cells secrete
cytokines similar to those produced by Th2 lymphocytes
[37].
A complex and tightly regulated process involving
multiple cell death-inducing mechanisms is also required
for elimination of excessive eﬀector T cells. Namely, it is
well known that within few weeks following the pathogen
clearance the vast majority (>90%) of eﬀector T cells die.
Beside negative signals blocking co-stimulation (CTLA-4)
and the onset of increased sensitivity to inhibition by several
cytokines, suchasTGF-β,the Fas/FasLinteraction represents
a key mechanism triggering eﬀector cell apoptosis, resulting
in the regulation of peripheral immune response. However,
a certain proportion of antigen-speciﬁc T cell eﬀectors is
salvaged and transformed into long-lived memory cells
which respond more rapidly and eﬀectively to pathogens
that they have encountered previously, thereby reﬂecting
the preexistence of the clonally expanded populations of
antigen-speciﬁc T lymphocytes [38]. A strong correlation
between memory cell production and the intensity of the
primary cellular response exists. Interestingly, irrespective of
the antigen quantity eliciting the immune response as well as
the TCR-MHC-antigenic peptide aﬃnities, the proportion
of eﬀector CD8+ T cells surviving the postresponse phase
in order to constitute the memory pool, is remarkably
constant. It is always about 5% to 10% of the maximal cell
numbers generated at the peak of the immune response.
Such surviving CD8+ T cells continue to express some of
the surface markers characteristic of activated cells, for
example CD44, but on the other hand they stop to do so
with others, like the early activation marker CD69, a C-type
lectin [39]. They also express more Bcl-2 protein, which
promotes cell survival, and have substantially higher normal
division rate (turnover) as well as apoptosis resistance in
vivo than na¨ ıve T lymphocytes. Two basic types of memory
CD8+ T lymphocytes exist, the early or polarized eﬀector
(TEM;C D 8 +CD27−CD45RA+CD62LloCCR7−NKG2D+)a n d
the resting or non-polarized central memory cells (TCM;
CD8+CD27+CD45RA
−CD62LhiCCR7+NKG2D+)[ 40]. It
has been shown that TCM home to lymph nodes, while the
TEM cells preferentially migrate to gut and other lymphoid
organs. The TEM cells can rapidly mature into eﬀector cells,
containing perforin as well as secreting large amounts of
IFN-γ, IL-4, IL-5, and low amounts of IL-2. They lack
CCR7 chemokine receptors but express high levels of β1
and β2 integrins, strong, adhesion molecules, that bind also
to extracellular matrix, suggesting that they can quickly
enter inﬂamed tissue. On the other hand the TCM cells
are smaller than the TEM ones and express CCR7, due to
which they continuously re-circulate through T-cell zones
of peripheral lymphoid tissues. As their fraction within the
total antigen-speciﬁc T lymphocyte pool is rather small,
they have a stem cell-like function in mounting strong recall
responses whenever they reencounter the antigen. In fact
they are very sensitive to antigen-speciﬁc TCR cross-linking
and in response to it rapidly express CD40L. However they
need more time to diﬀerentiate into eﬀector CTLs than
the TEM cells and also secrete less cytokines following their
restimulation. Namely, they produce only a certain amount
of IL-2 and low quantities of IFN-γ, IL-4, and IL-5. It has
also been shown in experimental animal models that the
immunological memory can be adoptively transferred to
na¨ ıve recipients and that the TCM cells provide longer lasting
immunity compared to the TEM ones [41].
3.Some Important FactorsInﬂuencingExVivo
Preparationof OptimalEffector CD8+ TC ells
for Adoptive Immunotherapy
3.1. Detection and Selection of Starting T-Cell Populations.
According to accumulating data it is very likely that precise
detection and careful selective isolation of potentially most
potent T cell subsets prior to their ex vivo expansion would
enormously increase their adoptive transfer eﬃciency. Target
T cell subset detection and selection can be performed
under GMP conditions by speciﬁc monoclonal antibodies
and speciﬁc antigenic peptide/selected HLA class I allele
tetramer-based immuno(para)magnetic separation (Isolex
300i; Clini-MACSR) or high-speed ﬂow cytometry-based
(FACS) cell-sorting as well as by the new non-aerosol-
generating microﬂuidic cell sorting devices (GigasortTM),
according to the expression of speciﬁc cell-surface markers
informative of their biologic or clonal eﬀector function.
Besidethemostcommonanti-CD3,anti-CD4andanti-CD8,
monoclonal antibodies can, for example, also be selected
to recognize and select for CD62L (L-selectin), a C-type
lectin leukocyte adhesion molecule; CCR7, a chemokineJournal of Biomedicine and Biotechnology 5
receptor related to cell homing, and various isoforms of
the protein tyrosine phosphatase CD45, that is, CD45RA
present on na¨ ıve/nonactivated and CD45RO on activated
T lymphocytes. It seems more and more so, that the
selectionofTCM (CD62hiCCR7+)lymphocytescouldprovide
astartingsourceofadoptivelytransferableimmunecellswith
improved in vivo persistence and therapeutic eﬃcacy [42].
In humans, peripheral blood, tumor tissue, and draining
lymph nodes have until now been sources of T cells for
adoptive transfer of antigen-speciﬁc immunity. Recently it
has become clear that bone marrow is a major reservoir of
self-reactiveTcellswithapotentialfortheiradoptivetransfer
premanipulation. For example, it has been shown that the
bone marrow of breast cancer patients contains CD8+ T
cell clones which speciﬁcally recognize peptides representing
the immunogenic part of the MUC1 and HER2/neu tumor
antigen aminoacid sequences, and also that, in pancreatic
cancer and myeloma patients, this haematopoietic compart-
ment is enriched for TAA-reactive CTLs [43]. Therefore it
remains to be determined whether or not the improved
antitumor eﬀects can be observed after adoptive transfer of
these speciﬁc CD8+ T cell clones.
3.2. CD4+ T-Cell Help. Due to the fact that IL-2 is needed
for eﬀective in vitro expansion of antigen-speciﬁc CD8+
CTLs, thereby providing conditions that at least partly
substitute the CD4+ T-cell help, it is quite obvious that a
concomitant presence of helper T cells is important for the
ex vivo production of high numbers of cytotoxic eﬀector
T cells. This statement is even more convincing as CD4+
T cell help is required for the onset and/or maintenance
of the CD8+ T cell memory, closely related to increased in
vivo survival of CTLs as well as for enhancing the cellular
immunity against tumors lacking MHC class II expression.
Namely, adoptively transferred CD4+ Tl ym p h o c yt e sa r ea b l e
to augment antitumor and antiviral immunity by several
mechanisms involving the enhancement of eﬀector CD8+ T
cell function and survival, secretion of essential cytokines,
such as IL-2 and IL-21 as well as expression of CD40L
[43]. It has been clearly demonstrated that the persistence
of adoptively transferred CD8+ eﬀector T cells increased
either with concomitant application of IL-2 or CD4+ T
lymphocytes[44].Finally,recentstudiesinmyelomapatients
have additionally shown that the adoptive transfer of mixed
populations containing antigen-speciﬁc CD8+ and CD4+
Te ﬀector T cells promoted the onset of immunity with
establishing a robust central memory component [45].
3.3. Cytokines. Beside IL-2, additional cytokines have been
extensively tested and some of them also used for ex vivo
preparation and in vivo transfer of adoptive immune cells.
The common gamma chain (γc; CD132) is a structural
component of IL-2, IL-4, IL-7, IL-9, and IL-15 binding
receptors. Cytokines that signal through γc are absolutely
indispensableforTcelldevelopmentinhumans[43].Besides
sharing the γc, IL-2 and IL-15 receptors also use a common β
chain (CD122) and induce T-cell growth-promoting stimuli
through Jak1 and Jak3 signalling pathways. The unique
IL-15α receptor is responsible for inhibition of activation-
induced cell death. Additionally IL-15 prevents Fas-induced
apoptosis and its presence overcomes tolerance of tumor-
speciﬁc T cells. Therefore a concomitant use of IL-2 and IL-
15seemstobeofbeneﬁtinadoptiveimmunecellpreparation
and transfer [46]. However, it has been recently shown
that IL-2 might also exert negative eﬀects by depleting
memory T cells and increasing the number of tumor-
protecting regulatory T cells (Tregs) [47]. By contrast, the
two homeostatic cytokines, IL-7 and IL-15 seem to increase
the persistence of CD8+ memory T lymphocytes and might,
therefore, decrease the ratio between Tregs and eﬀector T
cells [48].
3.4. Costimulatory Molecules and Their Counterreceptors.
Thesurfaceexpressionofcostimulatorymolecules,including
those pertaining to the B7 family (CD80, CD86, ICOS
ligand, the inducible costimulator ligand) and members of
the TNF family (4-1BB ligand, OX40 ligand), is induced in
APCs (macrophages, B cells, DCs) following their activation.
Except for CD28 which is constitutively expressed on resting
T cells, their counterreceptors (ICOS, 4-1BB, OX40) appear
exclusivelyonactivatedTlymphocytesrequiringseveraldays
to achieve peak densities. Their expression greatly dimin-
ishes when eﬀector CD8+ Tl y m p h o c y t e sd i ﬀerentiate into
memorycells.Thedelayedappearanceofthesecostimulatory
receptors on activated CD8+ T cells supports the hypotheses
that they are involved in sustaining the ongoing cellular
immune response as well as supporting the survival of the
newly induced CTLs [49]. Yet another molecule, the CD83,
a member of the immunoglobulin superfamily, which is
restrictively expressed on activated professional APCs, most
notably mature DCs, has recently been suggested to have
important role in priming na¨ ıve CD8+ Tl y m p h o c y t e sb y
drivingtheirantigen-speciﬁcexpansionandsupportingtheir
function as well as long-term survival (>6 months). Its
correspondingreceptors(CD83L)appearonantigen-speciﬁc
CD8+ T cells only following TCR and CD28 signalling [50].
Their engagement enhances proliferation of both, the newly
primed na¨ ı v ea sw e l la sm e m o r yC D 8 + T cells and inhibits
eﬀector cell apoptosis. Therefore CD83, together with
other costimulatory molecules, appears to be an important
candidate for standardized highly-eﬃcient antigen-speciﬁc
artiﬁcial antigen-presenting cell (aAPC) preparation which
is progressively substituting the classical use of autologous
professional APCs (DCs, monocytes/macrophages, B cells).
3.5. Telomere Length. Telomeres, composed of TTAGGG
repeats at chromosomal ends, are involved in cell prolifer-
ation and regulation of senescence. They also function as
tumor suppressors, protecting chromosomes from degra-
dation, fusion, and recombination. The telomeric repeats
are synthesized onto chromosomes by telomerase which
is a ribonucleoprotein enzyme. In all human cells, except
germ and stem cells as well as some activated lymphocytes,
telomeres lose a portion of their noncoding DNA repeats
with each division. This shortening of telomeric DNA
represents one of the mechanisms leading to cell senescence,6 Journal of Biomedicine and Biotechnology
so the telomere issue should be considered in preparing
immune cells for adoptive transfer. It has been shown that
in human CD8+ T lymphocytes telomeres are shorter in
CD8+CD27−CD45RA+TEM and CD8+CD27+CD45RA
−TCM
memory cell subsets as compared to the yet unprimed
CD8+CD27+CD45RA+ na¨ ıve T cell population [51]. There-
fore it seems probable that for optimal adoptive T cell
therapies the preservation of telomere length and replicative
life span capacity of memory cells is crucial for a long-term
immune protection, even more so, as it has recently been
shown that this correlates with the engraftment eﬃciency
and increased antitumor activity of adoptively transferred
T cells in melanoma patients [52]. In fact, TIL clonotypes
that were eﬀective and persisted in vivo had mean telomere
length of 6.2kb in comparison to 4.5kb within those,
that were not persisting. It is well known that in humans,
stem cells and lymphocytes, are able to induce telomerase
activity [53]. In eﬀector T cells, costimulatory signals are
required for this induction [54]. The CD28 co-stimulation
maintains telomere length in T cells, therefore the in vitro
cell culture conditions that promote costimulatory activity
might ameliorate engraftment and in vivo persistence of
adoptivelytransferredTcells.TheapplicationofIL-7andIL-
15 during the cell culture and/or after cell infusion could be
beneﬁcial as it has been shown that IL-15 induces sustained
level of telomerase activity, thereby minimizing telomere loss
in CD8+ memory T cells, even after substantial number of
their divisions [55, 56].
4. In VitroTests for Detection and
Functional Evaluation of Antigen-Speciﬁc
CD8+ Effector Cells
4.1. Cell-Mediated Lymphocytotoxicity (CML) and Limit-
ing Dilution Analysis (LDA). Standard 51Cr-release cell-
mediated lymphocytotoxicity (CML) assay is a classical test
in which the speciﬁcity and cytotoxic potential of CTLs, pre-
viously generated under deﬁned cell culture conditions, are
assessed. By establishing microcultures, containing diﬀerent
eﬀector to Na51CrO4-containing speciﬁc target cell ratios
(E : T) and their subsequent 4 hour incubation at 37◦C, the
amount of 51Cr, speciﬁcally-released from destroyed targets
is ﬁnally detected by a γ-counter [57].
With a use of limiting dilution assay (LDA), antigen-
speciﬁc CTL precursor (CTLp) frequencies can be deﬁned
in a population of PBMCs by performing assay evaluation
based on Poisson distribution statistical analysis. At least 24
replicate microcultures for each of seven diﬀerent, normally
twofold dilutions of responding PBMC are set up and
cultured for a deﬁned period of time in the presence of a
constant number of stimulator cells and rhIL-2. Constant
numbers of speciﬁc, Na51CrO4-containing speciﬁc target
cells are then added to each microculture. After additional
4 hour incubation at 37◦C, the supernatants are harvested
and the CTL activity assessed by measuring the amount
of 51Cr, speciﬁcally-released from destroyed targets in each
microcultures.TheCTLpfrequencycanbedeterminedboth,
statistically by applying minimum χ2 and/or maximum
likelihood analysis and graphically, by plotting on the log
scale the percentage of negative microcultures (ordinate)
against the numbers of responding cells per each dilution
(normal scale, abscissa); the plot should result in a straight
line [58].
4.2. Enzyme-Linked Immunospot (ELISPOT) and Multipa-
rameter Flow Cytometry-Based Intracellular Cytokine Staining
Assays (ICS). The ELISPOT assay has been developed from
a traditional ELISA technique and is used for detecting
and evaluating local concentrations of selected cytokines
producedbyindividualantigen-activatedTcells,forexample
IFN-γ secreted by activated CD8+ eﬀector T cells [59, 60].
A capture, cytokine-speciﬁc antibody is ﬁxed on a pre-
coated polyvinylidine ﬂuoride (PVDF) plate and blocked
with a serum. Subsequently the cells are added together
with an appropriate stimulant and the plates incubated to
allow the antibodies to bind the speciﬁc cytokine. After
washing, a biotinylated antibody is added to enable detection
of the captured analyte, followed by the individual, cytokine
producing cell visualization step, requiring the addition of
avidin-HRP (HRP—Horse Radish Peroxidase) or avidin-
ALP (ALP—Alkaline Phosphatase) conjugate and a coloured
precipitating substrate. The ELISPOT assay is very sensitive
and allows quantitative as well as qualitative assessment of
the cytokine production.
Upon recognition of their cognate antigen, the subse-
quently fully activated T cell clones start to produce a range
of diﬀerent cytokines that can be detected within a single cell
by ICS assay. In order for this to be possible, the secretory
pathway of selected cytokines must be blocked by Brefeldin
A, a metabolite of fungus Eupenicillium brefeldianum that
speciﬁcally blocks protein transport from the ER to the Golgi
apparatus, thereby causing their intracellular accumulation,
which in turn can be detected by appropriate antibody
staining and ﬂow cytometry [60, 61].
4.3. HLA Class I Multimer-Based Assays. The ﬁrst reagents
of this kind were HLA class I tetramers that were at ﬁrst
used for in vitro quantitative determination of CD8+ Tc e l l
clones according to the aﬃnity and binding speciﬁcity of
their TCRs, to a deﬁned tetrameric HLA class I/antigenic
peptide complex. First, soluble α chains of target HLA
class I molecules, bearing speciﬁc amino acid sequence at
their carboxyl terminus, recognised by the enzyme BirA,
are synthesised by E. coli. After the addition of beta-2
microglobulin (β2m) and the chosen antigenic peptide, the
soluble HLA molecules are correctly folded and in the
presence of BirA, one biotin per HLA molecule is attached.
When ﬂuorochrome-tagged streptavidin, a molecule with
four biotin-binding sites is added, homogenous tetrameric
HLA class molecule/antigenic peptide complexes are formed
possessing high aﬃnity for binding cognate TCRs [58].
Such tetramers are then used, together with other ﬂuo-
rescently labelled monoclonal antibodies speciﬁcally recog-
nising deﬁned T cell-speciﬁc surface molecules, for precise
quantitative characterisation of target T cell clones. As
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from fresh peripheral blood and tumor tissue or previ-
ously ex vivo activated PBMCs, remain viable, they can
be selected by cell sorting, for further characterization
and/or expansion. Recently improved reagents, that is,
pentameric HLA class I allele/antigenic peptide complexes
were developed and are commercially accessible (Pro5
MHC Class I Pentamers, Proimmune). Due to their planar
conﬁguration, all ﬁve HLA-peptide complexes, assembled
through a coiled-coil domain, are available for binding
to complementary TCRs, while in tetramers, due to the
tetrahedral spatial organization, only three out of four
MHC-peptide complexes are available for TCR interac-
tion.
5. Endogenous and ExVivoInduced
Antigen-SpeciﬁcCD8+ TCells,Expanded
InVitroforSubsequentAdoptive
Immunotherapy
During recent decades the procedures for ex vivo selection,
isolation and propagation of antigen-speciﬁc eﬀector cells
pre-primed in vivo or induced in vitro have been suc-
cessfully developed, allowing preparation of clinical-grade
CTL eﬀectors, directly targeting various tumor associated
antigens (TAA) as well as diﬀerent viruses, for example
cytomegalovirus (CMV), Epstein-Barr virus (EBV), ade-
novirus (ADV), herpesvirus (HPV), human immunodeﬁ-
ciency virus (HIV) and inﬂuenza-A virus.
5.1. Tumor-Inﬁltrating Lymphocytes (TILs). Autologous TILs
can be obtained from excised solid tumors, tumor-draining
lymph nodes and even from peripheral blood of cancer
patients, sometimes following the precedent vaccination
with TAA in order to increase the frequency of circu-
lating anti-tumor precursor immune cells. Unfortunately
only 30–40% of all tumor biopsies have been reported
to yield satisfactory T cell populations [46]. For example,
≥1cm 3 pieces of freshly resected metastatic melanomas
were required for obtaining suﬃcient starting numbers of
TILs [62]. The relatively small amounts of TILs that can
be isolated from diﬀerent types of cancer tissue biopsies,
represent a polyclonal mixture of diﬀerent immune cell
types: CD4+ and CD8+ T lymphocytes, NK cells, DCs,
monocytes/macrophages and B cells. By using appropriate
cell culture conditions, favouring T lymphocyte prolif-
eration, a massive expansion of pre-selected TILs, while
retaining their antigen speciﬁcity, is technically feasible and
can result, within several weeks, in a ﬁnal dose of >1010
clinically applicable cells [42]. The re-infused CTLs can
make up to 37% of the total transferred TIL population.
Immediately after cell isolation from fresh biopsies, multiple
cell cultures are established, separately grown and then
assayed in vitro for speciﬁc T cell tumor recognition,
for example by using ELISPOT tests, detecting cytokine-
secreting activated eﬀector cells. Only those single cultures
that exert high anti-tumor T cell reactivity are then selected
for massive expansion.
The use of deﬁned serum-free media (X-VIVO or AIM-
V), usually high doses of recombinant human IL-2 (rhIL-
2)—up to 6000U/ml, γ-irradiated allogeneic peripheral
blood mononuclear cells (PBMCs) or clinical-grade EBV-
transformed B lymphoblastoid cell lines (LCLs) as feeder
cells, enable the creation of optimal T cell expanding culture
conditions that can be standardized and applied within
the constraints of the good manufacturing practice (GMP)
[42]. Under such, so-called rapid expansion protocol (REP)
conditions, developed by Riddell et al., TILs can be poly-
clonally stimulated by a combination of anti-CD3 (OKT3)
and anti-CD28 antibodies, with the ﬁrst ones triggering the
initial Tcellactivation signalthroughcross-linking ofCD3-ζ
elements of the TCR complex and the second ones providing
proper costimulatory signals following their interaction with
CD28 molecules [63]. The use of PBMC/LCL feeders can be
substitutedby variouskinds ofantigen-non-speciﬁc artiﬁcial
APCs (aAPCs), equipped with number of surface bound
T cell activating and costimulatory molecules: anti-CD3
antibodies; anti-CD28 antibodies and other costimulatory
signal and prolonged TIL lifespan providing molecules, such
as 4-1BB, CD40 and adhesion molecule co-stimulator OX40
(CD134), a member of the TNF family. Such aAPCs can also
be prepared in a standardized way under GMP conditions.
Forthispurposemagneticbeads,onwhichtheactivatingand
costimulatory molecules can be bound chemically or alter-
natively the MHC class I-negative leukaemia cell line K562,
transfected with 4-1BB and CD32 (FcγRII), a low aﬃnity Fc
receptor (K32 cells) which represents the anchor for anti-
CD3 and CD28-speciﬁc antibodies, have successfully been
used [64, 65]. However, these non-speciﬁc aAPCs preferen-
tially expand CD4+ in comparison to CD8+ T cells, which,
during the process, additionally lose a signiﬁcant proportion
of their antigen-speciﬁc CTL activity unless a proper in vitro
antigen-speciﬁc re-stimulation is provided. Therefore new
approaches in developing aAPCs will be needed for eﬃcient
exvivogenerationoflargeamountsofantigen-speciﬁcCD8+
TILs. Recently it has been reported that aAPCs, generated
by using biotinylated activating (anti-CD3), costimulatory
(anti-CD28) and adhesion (anti-LFA-1; CD11a) monoclonal
antibodies, pre-clustered in microdomains, established on
liposome scaﬀolds by pre-inserted neutravidin rafts, could
eﬃciently induce expansion of endogenous antigen-speciﬁc
CTLs [66]. However, prolonged stimulation/expansion of
CD8+ TILs causes their terminal diﬀerentiation, exhaustion
and shortens their life span in vivo.
As IL-2 is crucial for eﬀective TIL expansion, the moni-
toringbyﬂowcytometryoftwoimportantfactorsinvolvedin
IL-2-mediated T cell activation, namely CD27 costimulatory
molecule, a member of the TNFR family, expressed on non-
activated T cells, NK cells as well as on some B cells, and
its CD70 molecular ligand that is abundantly present on
the surface of activated T cells, B cells and macrophages,
has revealed important insights regarding their molecular
dynamics and function. Namely both, in vivo and in vitro
application of high IL-2 concentrations up-regulates the
CD70 and at the same time blocks the expression of CD27
molecules on the surface of CD8+ T cells. The withdrawal
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maintained in the presence of the cytokine, results in a
reversal of the expression of these two molecular markers.
The proliferation of T cells, stimulated with IL-2, primarily
o c c u r si nas u b s e to fC D 8 +CD70+ T cells that have up-
regulatedIL-2receptorexpression,butnotinCD8+CD70− T
lymphocytes. Furthermore, the analysis of TIL samples that
were administered to melanoma patients showed that the
size of the CD8+CD27+ T cell pool within each particular
bulk TIL preparation was highly associated with the induced
antitumor activity [67].
5.2. Adoptive Transfer of Endogenous Virus-Speciﬁc CTLs.
Viral infections represent a major cause of morbidity and
mortality during the ﬁrst,highlycritical 100days ofthepost-
transplantation immune recovery of myeloablatively pre-
conditioned patients, having received haematopoietic stem
cell (HSC) transplantation with a concomitant immuno-
suppressive medication. Therefore, adaptive transfer of HSC
donor-derived antiviral CD8+ T cells represents eﬀective
treatment resulting in reconstituted antiviral immunity in
such heavily immunocompromised recipients. The simplest
approach is to use unmanipulated donor lymphocyte infu-
sions (DLIs), containing high frequencies of virus speciﬁc
eﬀector T cells recognizing and eliminating common latent
viruses, such as CMV and EBV. Otherwise, DLIs are quite
routinely administered to generate graft versus leukaemia
eﬀect (GvL) in those HSC transplanted patients that have
relapsed after they had been tapered oﬀ immunosuppressive
drugs, with no evidence of severe graft versus host disease
(GvHD).Detection,isolationandexvivoexpansionofvirus-
speciﬁc CTLs originating from allogeneic, MHC haploiden-
tical or identical (siblings) CMV and/or EBV seropositive
individuals have also been successfully carried out and
the resulting cell preparations used for treating viremia as
well as post transplant lymphoproliferative disease (PTLD)
and virally caused malignancies in immunocompromised
patients. Anyhow, DLIs and other allo- or semiallogeneic
cellularproductscontainahighfrequencyofalloreactivecells
that could give rise to GvHD. Therefore, in order to reduce
this risk, donor T cells can be transduced with suicide genes
which are triggered if the recipient develops GvHD. In this
way, such cell preparations can be administered already early
post transplant, reconstituting virus-speciﬁc immunity and
at the same time allowing control over GvHD. The most
commonly used and clinically tested is the herpes simplex
virus thymidine kinase (HSV-tk) that renders transduced
T cells sensitive to the antiviral drug ganciclovir [68].
Unfortunately this enzyme is a foreign antigen to recipient
and therefore the transduced cells can be quickly eliminated
by CTLs. Therefore new non-immunogenic suicide genes
based on the Fas- and Caspase 9-FK-binding domain
chimeras have been prepared that are able to induce target
T-cell apoptosis via dimerization process, activated by a
non-toxic chemical substance [69]. Alternatively, selective ex
vivo depletion of alloreactive T cells has also been used to
minimize the perils of generating GvHD after the adoptive
transfer and proved to be successful, as small numbers of
residual MHC haploidentical donor cells accelerated anti-
viral immune responsiveness in the recipient [68].
5.3. Cytomegalovirus (CMV). CMV is a lytic virus, latently
present in approximately 70% of healthy individuals. Cell-
mediated immunity is considered to be crucial in controlling
the infection with both CD4+ and CD8+ T cells importantly
involved in antiviral immune protection. This has been
proven in several cases where CMV-speciﬁc CTLs were
infused into patients 30–40 days post HSC transplantation
and were found eﬀective but persisted only in those recip-
ients whose CD4+ T-cell-mediated CMV-speciﬁc immune
responses were recovered [70]. Also, when both CMV-
speciﬁc CD4+ and CD8+ T cells were transferred into
patients,long-termpersistingimmunitywasachieved[71].A
majority of anti-CMV CTL therapies described till recently,
required long periods of ex vivo CD8+ T-cell activation
and expansion in the presence of IL-2, and were depending
on specialized GMP conditions. Recently, tetramer MHC-
based selection of CMV pp65 peptide-speciﬁc T cells directly
from peripheral blood, their subsequent adoptive transfer,
resulting in their expansion by several logs in vivo and a
successful clearance of infection in the majority of recipients,
has been reported [72]. By using another approach, DCs
were prepared from adherent fraction of fresh PBMCs
isolated from CMV seropositive HSC donors and used to
stimulate autologous T lymphocytes for 21 days in the
presence of IL-2. Direct positive immunomagnetic selection
of same donor IFN-γ-secreting T cells from leukapheresis
units,followingashortpre-incubationwiththerecombinant
CMV-speciﬁc pp65 antigen, was also carried out. Both
alternatively generated CMV-reactive T cells were successful
in accelerating reconstitution of antigen-speciﬁc immunity
in patients following HSC transplantation [73]. Eﬃcient
CMV-reactive CD8+ and CD4+ T cells can also be prepared
byusingselectedsinglehumanleukocyteantigen(HLA)class
I or class II allele-speciﬁc aAPCs. Mouse 3T3 ﬁbroblasts were
therefore sequentially transduced with retroviral vectors to
expresshumancostimulatory(B.71)andadhesion(ICAM-1,
LFA-3)molecules,β2-microglobulinandαchainsofdiﬀerent
HLA class I alleles (A∗0201, A∗0301, A∗2402, and B∗0801).
Such aAPCs were then transduced to co-express a full length
antigenic CMVpp65 protein and were able to elicit strong
HLA-restricted anti-CMV CTL responses, not only against
dominant but also subdominant pp65 antigenic epitopes, as
clearly shown by the particular peptide/HLA class I allele
tetramer binding assays in vitro [74].
5.4. Epstein-Barr Virus (EBV). EBV is a γ-herpesvirus,
latently infecting more than 95% of the world’s population.
There are at least four known types of viral latency,
characterized by expression of numerous diﬀerent EBV-
speciﬁc antigens with prevalently low and rarely high
immunogenicity that are related to diﬀerent diseases [68].
Whilethetype1iscommontoBurkittlymphomaandgastric
carcinoma, the type 2 is observed in Hodgkin lymphoma,
nasopharyngeal carcinoma, NK and T cell lymphomas and
other mucosal carcinomas, with both types obviously being
able to evade immune surveillance due to a combination
of low immunogenicity of expressed EBV-related proteins
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IL-10, produced by reactive T lymphocytes and the Reed-
Sternberg cells [75]. On the other hand the type 3 latency,
involving genes coding for all EBV-associated proteins, also
the most immunodominant nuclear antigens, EBNA3A, -
3B and -3C, being appropriate targets for immunotherapy,
is responsible for causing lymphoproliferative disorders,
but only in severely immunocompromised patients having
received allogeneic HSC or organ transplants (PTLD), being
congenitally immunodeﬁcient or HIV-infected.
The EBV-infected B cells in PTLD express the same
phenotype and virus-speciﬁc antigens as experimentally
used EBV-transformed lymphoblastoid cell-lines (LCLs),
prepared in vitro by infecting peripheral blood B lympho-
cytes with a laboratory strain of EBV. As EBV-transformed
LCLs can be readily generated from any donor, they are
used as APCs for preparing clinical grade polyclonal anti-
EBV CD4+ and CD8+ eﬀector T lymphocytes, recognizing
multiple latent and lytic viral antigens. In this way high
numbers, that is, >107/m2 of EBV-reactive CTLs can be
produced, which are suﬃcient for repeated cycles of their
adoptive transfer [76, 77]. Such adoptively transferred CTL
eﬀectors survive up to eight years in the recipient and can
expand up to 2–4 logs after infusion [68].
Unfortunately nasopharyngeal cancer (NPC) and
Hodgkin disease (HD) do not express immunodominant
EBV antigens, instead the subdominant EBNA1 is
characteristic of NPC and the latent membrane proteins
1 and 2 (LMP1, LMP2) for HD and 50% of NPCs [78].
Clinical trials in which CTLs speciﬁc for these antigens
were used for treatment, have only been partially successful.
In order to improve their potency, the subdominant EBV
antigen-speciﬁc CTLs were genetically modiﬁed ex vivo to
make them TGF-β resistant [79].
5.5. Adenovirus (ADV). Adenovirus is a non-enveloped
lytic DNA virus with 51 serotypes, forming six distinct
groups (A-F). The adenovirus infection is very frequent in
paediatric HSC transplantation. A group of patients with
ADV infection were successfully treated with a combination
of virus-speciﬁc polyclonal CD4+ and CD8+ Tl y m p h o c y t e s
obtained from HSC donors, shortly stimulated in vitro
with viral antigen, actually a lysate, prepared from ADV
Spc-infected human embryonic lung ﬁbroblasts (HELF),
subsequently immunomagnetically selected according to
their IFN-γ production and then expanded in the presence
of IL-2 and feeder cells [68, 80].
5.6. Multivirus-Reactive T cells. Such pluripotent antiviral T
lymphocytes, able to eradicate CMV, EBV and adenovirus
infected cells, can be generated and expanded in vitro by
using autologous or donor-derived PBMCs transduced with
a recombinant adenoviral vector, encoding for the highly
immunogenic CMV antigen pp65 as stimulators. Subse-
quently, EBV-transformed LCLs, transduced with the same
vector are added as APCs, thereby additionally activating
EBV -speciﬁcTcellsaswellassupportingpreviouslyactivated
anti-CMV and adenovirus reactive T lymphocytes [81]. The
application of such ex vivo induced and expanded polyclonal
CTLs resulted in relevant, clinically detected clearance of
combined infection with all three viruses. Alternatively,
DCs can also be used as eﬃcient inducers of adoptively
transferable anti-multiviral T cell eﬀectors.
6. InVitroInduction/Engineering
and Expansion of Clinical-Grade
Antigen-SpeciﬁcCTLs
Besides the direct use of endogenously developed CTL
responders that can optionally be additionally ampliﬁed
before their expansion ex vivo, de novo engineered antigen-
speciﬁc HLA class I-restricted immune reactions can also
be induced in vitro by using responding PBMC population
and various types of stimulating APCs, either the natural
professional or artiﬁcially created ones.
6.1. Professional APCs. Professional antigen presenting cells,
macrophages, B cells and the most potent DCs possess
all the necessary machinery for antigen uptake, processing
and MHC-restricted presentation as well as costimulatory
signalization and cytokine production. The most frequently
exploited for antigen-speciﬁc CTL generation are DCs which
can be prepared in vitro either from bone-marrow-derived
CD34+ cells or, prevalently from easily accessible peripheral
blood CD14+ monocytes [82]. Besides the optimal in vitro
preparation of DCs, the most eﬀective antigen loading
method is the next crucial step in providing strong and
speciﬁc (re)activation of T cells. Of special interest is the pre-
sentation of TAAs. As some of them, especially those speciﬁc
for melanoma, are well deﬁned, synthetic antigenic peptides
withhighbindingaﬃnitytospeciﬁcHLAclassIallelescanbe
used. Alternatively native peptides eluted from HLA alleles,
expressed on the surface of tumor cells can be applied. Also
whole proteins or tumor cell preparations (apoptotic cells,
cell lysates) can be delivered to immature DCs which have a
strong capacity to uptake, process and present their peptide
fragments within the context of both, HLA class I and class II
molecules. Following their maturation, such antigen loaded
DCs are strong inducers of speciﬁc CD4+ and CD8+ T
cell immune responses. Whenever appropriate amounts of
tumor cells are available, hybrid cells following their chem-
ical or electrofusion with DCs can be produced, therefore
combining the whole spectrum of TAA and stimulatory
propertiesofprofessionalAPCs.Wehaverecentlyshownthat
the amount of fused late endocytic compartments correlates
with the potency of in vitro CTL responses generated with
electrofused tumor cell-DC hybridomas [83]. Also tumor-
derived DNA and especially RNA can be transferred into
DCs,therebyproviding thegeneticinformation forcomplete
TAA spectrum to be produced, processed and eﬃciently
presented to T cells. Several laboratories, including ours
proved the eﬀectiveness of native and/or ampliﬁed tumor
mRNa transfection in generation of potent antitumor CTLs
[57, 82]. The mRNA transfection approach oﬀers a practical
solution, obviating the need for extensive amounts of tumor
tissue which can be a limiting factor for antigen-speciﬁc DC
preparation.10 Journal of Biomedicine and Biotechnology
It is also still not clear to what extent DCs depend on
the concomitant presence of CD4+ T cells in the induction
of CTLs. Nevertheless the promoting eﬀect on CD8+ T
lymphocyte diﬀerentiation has been clearly shown for a
number of cytokines, for example IL-2, IL-12, IFN-γ and
IL-15. Manjutah et al. have shown that a certain threshold
concentration of IL-2 is needed for the CTL eﬀectordiﬀeren-
tiation from their precursors, while IL-15 alone or the sub-
treshold concentrations of IL-2 can only promote CD8+ T-
cell proliferation and their IFN-γ production [84].
6.2. Artiﬁcial Antigen-Speciﬁc APCs (aAPCs). Besides the
already mentioned use of standardised “oﬀ the shelf”
antigen-non-speciﬁc aAPCS, HLA-allele/antigenic peptide
complex transduced surrogates of natural professional APCs
can also be engineered and subsequently used in vitro to
induce tailored antigen-speciﬁc cytotoxic immune responses
of CD8+ T lymphocytes that can be adoptively transferred
into patients. Two basic approaches for preparing MHC-
class I-antigenic peptide or MHC-class II-antigenic peptide
speciﬁc aAPCs, using either cell lines or acellular systems,
can be used. HLA class I antigen-speciﬁc aAPCs, able to
eﬃciently stimulate CD8+ cells can for example be produced
by using the following:
(a) drosophila melanogaster cells which are unable to
load endogenous peptides on the nascent HLA class
I molecules, additionally expressing costimulatory
molecules (CD80 and CD54); unfortunately these
insect cells are rather rapidly eliminated at 37◦C,
resulting in massive release of antigens and need
additionalfeedercellsinordertoactaseﬀectiveAPCs
[64];
(b) murine 3T3 ﬁbroblast cell line, transduced with
CD80 (B7.1), CD54 (ICAM-1) and CD58 (LFA-3)
and a selected HLA class I allele [64, 65];
(c) K32, a CD32 (human low aﬃnity Fcγ receptor)-
transfected precursor K562 chronic erythroleukemic
cell line, constitutively expressing exclusively HLA-
C molecules, but also B7-H3, ICAM-1, LFA-3 and
showingTcell-dependentupregulationofPD-1Land
PD-2L; only after transfection with 4-1BBL and after
beingcoatedbyHLAclassItetramersorIg-HLAclass
I fusion molecules or transfected with HLA class I,
CD54, CD58, CD80 and CD83, these cells could then
be used as antigen-speciﬁc aAPCs [64, 85];
(d) exosomes, which are cell-derived vesicles, about 60–
90nminsize,containedwithinlargerendosomesand
secreted into the extracellular space after endosomes
fuse with a plasma membrane; they can stimulate
immune responses in vivo and antigenic peptides can
be directly loaded onto puriﬁed exosomes [64];
(e) liposomes, for example composed of cholesterol
and a neutrally charged phospholipid phosphatidyl-
choline as scaﬀolds accommodating HLA molecules
[64];
(f) magnetic beads, coated with Ig-HLA class I fusion
molecules and anti-CD28 antibodies [64, 65, 86];
(g) latex microspheres coated with HLA-class I-antigenic
peptide complexes or HLA class I-antigenic peptide
tetramers, costimulatory molecules CD80, CD83,
CD54 and/or anti-CD28 antibody, in the presence or
absence of autologous PBMCs as feeder cells [65, 87,
88];
(h) soluble HLA class I-antigenic peptide monomers,
cross-linked with anti-CD27 or anti-CD-28 costimu-
latory antibodies onto a streptavidine core molecule
[89].
6.3. Genetically Engineered Antigen-Speciﬁc CTLs. An alter-
native to selecting speciﬁc antitumor or anti-pathogen T
cell clones from patients, is to engineer such immune
reactivity by transferring genes coding for clonally speciﬁc
αβTCRs or single-chain chimeric antigen receptors (CARs),
therefore obviating the prolonged antigen-driven T cell
selection [90]. Genes encoding TCRs can be isolated from
pre-selected(captureofIFN-γ secretingCD8+ cellsfollowing
speciﬁc antigenic stimulation or the use of HLA allele-
antigenic peptide multimers) high avidity human T cells or
T cells from transgenic mice immunised with human cancer
antigens, subsequently cloned and inserted in retroviruses
[62]. The Vβ usage in selected high aﬃnity clonal TCRs can
be deﬁned by TCR Vβ-repertoire analysis, based on a panel
of monoclonal antibodies, recognizing approximately 70%
of TCR Vβ families, and ﬂow cytometry [91]. Additionally,
by performing TCR Vβ spectratyping, that is, multiplex real
time PCR (RT-PCR) reactions, T-cell repertoire diversity
can be analyzed by comparing the relative frequencies of
diﬀerent clonal length products within the CDR3 region
of a particular TCR Vβ family [92]. The genes encoding
for high aﬃnity tumour antigen-speciﬁc αβTCRs have been
successfully transduced into patients’ autologous T cells
by using retroviral vectors and were clinically tested [93].
However the production and testing of retroviral producer
cell lines and clinically applicable GMP batches of virus
remain expensive and time consuming. Additionally, the
discovery of transgene-containing lymphoid malignancies
in children treated with retrovirally transduced HSC, has
discouraged the use of this vector system for genetically
manipulated T cell adoptive transfer trials [42]. Therefore
the use of naked DNA and electroporation is being studied
as an alternative approach, as it has been proven to be
safe, reproducible and economically feasible, but may be
limited by the time needed for selection of T cells containing
stable genomic transgene integrants. It seems that a proper
compromise would be to use DNA transposon/transposase
elements which can eﬃciently and safely transfect T cells and
can be manufactured under clinically grade GMP conditions
[42]. But there are also other pitfalls of αβTCR gene transfer,
for example:
(i) many tumors can evade immune surveillance by
down-regulating or completely abrogating MHC
expression;Journal of Biomedicine and Biotechnology 11
(ii) a detailed knowledge regarding patient’s HLA allele
speciﬁcities is required in order to maintain speciﬁc
antigen recognition by cloned TCRs;
(iii) the speciﬁcity of transferred α and β chain pairs
can be altered due to their unwanted pairing with
endogenous αβ TCR chains in the recipient cells,
potentially resulting in autoreactive receptors.
To limit the latter mispairing problem, the newly intro-
duced αβ TCR chains can be fused to CD3-ξ or their
constant domains equipped with cysteine residues in order
to facilitate additional inter-chain disulﬁde bond formation.
Alternatively their TCR constant domains can be replaced
with those of murine origin [42].
By using CAR technology, many pitfalls of αβTCR
transfer, especially those, related to HLA antigen restriction,
can be avoided. CARs are constructed out of an antigen-
recognizing extracellular domain, in most cases a single-
chain antibody fragment (scFv) containing the heavy (VH)
and light (VL) variable chains, fused to an intracellular T-cell
signallingdomain,usuallytheCD3ξ-chainprovidingthecell
activation signal. Costimulatory molecules such as 4-1BB,
OX40 and ICOS can also be added to promote full activation
of CAR+ CD8+ T cells [94]. The use of CAR-transduced
CD8+ T lymphocytes seems to be ideal for targeting B-cell
malignancies, but clinical studies involving other types of
cancer are also being performed [95, 96].
Gene modiﬁcation can also be used to enhance T-
cell function, for example by conferring a helper T-cell
independent phenotype to CD8+ T lymphocytes, either with
the transfer of chimeric GM-CSF-IL-2 receptor, restoration
of CD28 expression or the expression of the catalytic
subunit of telomerase, thereby enabling speciﬁc antigen-
driven autocrine proliferation as well as rejuvenation of the
CTL eﬀector pool [46].
7.OptimalCellDoseforA dopti v elyT ransferr ed
CD8+ TCell-BasedCellularProducts
The optimal or at least the minimal T cell dose to be
adoptively transferred into recipient in order to obtain
desirable therapeutic eﬀect, are still not known. However, we
can speculate that they are dependent on many important
factors, such as
(i) manufacturing conditions enabling the production
of highly eﬃcient antigen-speciﬁc, long-term in vivo
persisting eﬀector cells;
(ii) recipient’s condition at the time of the adoptive cell
transfer (nonmyeloablative lymphodepleting pre-
conditioning is crucial);
(iii) tumor type, tumor size or degree of viremia;
(iv) relative densities and aﬃnities of counterreact-
ing eﬀector cell antigen-speciﬁc immunoreceptors
(TCRs) and TAA or viral antigens presented as
antigenic peptides within the context of recipient’s
MHC molecules, expressed on target cells [42].
Anyhow, therapeutic eﬀects have been reported for a
substantial variety of cell concentrations that were used to
adoptively treat diﬀerent diseases, for example
(i) 0,2 × 105–1 × 105 CMV-speciﬁc T-cell lines/kg,
administered in a single infusion [97];
(ii) 5 × 106–1 × 108 multi-virus–reactive cell line/m2,
administered in a single infusion [98];
(iii) 4×107–3×108 EBV-speciﬁcT-cells/m2,administered
in 1 or 2 infusions [99];
(iv) 0,11–13,1 × 108 melanoma-speciﬁc T cells/infusion,
administered in at least 3 infusions [100];
(v) 2,3×1010–13,7×1010 melanoma-speciﬁc T cells/in-
fusion [101];
(vi) ∼5 × 1010 ex vivo selected and expanded autol-
ogous TILs isolated from metastatic melanoma
patients/infusion [102].
8. Preconditioning of Patients Receiving
AdoptiveTransferofAntigen-SpeciﬁcTCells
Numerous animal experiments as well as clinical stud-
ies in humans have clearly shown that the eﬀective-
ness of adoptively transferred T cells can be augmented
when combined with conventional cytotoxic agents such
as cyclophosphamide, doxorubicin, paclitaxel, ﬂudarabine
and sometimes also with a low-dose irradiation [103].
Therefore the nonmyeloablative lymphodepletion of the
host, preceding the adoptive immunotherapy became one
of the crucial components of the treatment as it has
been proven that it eliminates recipient’s tumor-protecting
regulatory/suppressor T cells as well as cytokine sinks,
that is, lymphocytes that compete with the transferred
immune cells for homeostatic γc cytokines, such as IL-7
and IL-15 which enhance CD8+ Tc e l la c t i v i t y[ 103]. For
example, in clinical trials, where the eﬀects of adoptively
transferred autologous in vitro expanded TILs, obtained
from metastatic melanoma patients, combined with a
high-dose of recombinant human IL-2 were studied, the
lymphodepletion prior to cell and cytokine infusion was
achieved by cyclophosphamide (60mg/kg during the ﬁrst
2 days) and ﬂudarabine (25mg/m2 during the next 5
days). More than 50% of treated patients experienced an
objective clinical response and few of them were considered
complete responders [104, 105]. In some patients with a
noticeable tumor regression, a large in vivo expansion of
transferred antitumor-speciﬁc lymphocytes was observed.
These CD8+ T cells with a single Vβ7T C Rc l o n o t y p e
persisted in high percentages (>70%), relative to total
numbers of lymphocytes, for several months [104]. But
regardless of the promising results obtained so far, the
optimal lymphodepletion conditioning regimen obviously
still has to be deﬁned.12 Journal of Biomedicine and Biotechnology
9. Conclusions
Enormous progress in understanding T cell biology and
physiology, combined with the evolution of sophisticated
technologies for generation, detection, selection, and clonal
expansion of MHC class I-restricted antigen-speciﬁc CTLs
have made the adoptive transfer of these and other immune
cells into previously non-myeloablatively pre-conditioned
patients, a rather eﬀective clinical procedure with a highly
promisingperspective.Increasingnumbersofclinicalstudies
with encouraging preliminary results are a vivid driving
force for the ever-competing research and innovation within
t h i sﬁ e l d .T h r o u g ha l lt h i sp r o g r e s si ti sb e c o m i n gm o r e
and more obvious that in order to be successful, various
c o m b i n e da p p r o a c h e ss h o u l db eu s e dt oe ﬃciently modulate
immune responses, which is undoubtedly most obvious in
antitumor immunotherapy. The fact that only lymphode-
pleted hosts can beneﬁt from adoptively transferred anti-
TAA-speciﬁc T cells has clearly shown that besides providing
highlyspeciﬁcantitumorresponses,deblockingofnumerous
tumor-protective mechanisms among which some of the
most pronounced are sustained by tolerogenic and anergic
immunecells,isvitalforthiskindoftherapytobesuccessful.
Another critical issue, crucially related to development of
immunotherapy is the obligatory concordance of all proce-
dures involved in the preparation of cellular products, with
more and more strict regulations demanding the fulﬁllment
of GMP standards. It seems that the regulative has somehow
overtakentheprovidersofreagentsandequipment,therefore
creating certain problems resulting in late translation of
experimental achievements into the clinical practice. This of
course is also a consequence of lacking funds for very costly
phase III clinical studies and registration of such cellular
drugs.
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